Dupilumab in patients with cold urticaria: Results from a phase 3 trial
Dupilumab treatment did not lead to statistically significant improvements in signs and symptoms of ColdU as compared with placebo over the 24-week treatment period.
Authors
- Allen R. Radin (ORCID: https://orcid.org/0009-0003-0736-8115)
- Akiko YAGAMI
- Lacey B. Robinson (ORCID: https://orcid.org/0000-0002-0008-2902)
- Melanie Makhija
- Martin Metz
- Ana M. Giménez-Arnau
- Xiaodong Luo
- Renata Martinčová
- Sarbjit S. Saini
- Rémi Gagnon
Institutions
- Johns Hopkins University (US)
- Fujita Health University (JP)
- Universitat Pompeu Fabra (ES)
- Regeneron (United States) (US)
- Johns Hopkins Medicine (US)
- Morristown Medical Center (US)
- Sanofi (France) (FR)
- Humboldt-Universität zu Berlin (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- C3I (United States) (US)
- Sanofi (Czechia) (CZ)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1016/j.jacig.2026.100673
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00